These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 33305478)

  • 21. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
    Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
    Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologics in the treatment of asthma in children and adolescents.
    Bacharier LB; Jackson DJ
    J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asthma biologics: Comparing trial designs, patient cohorts and study results.
    Doroudchi A; Pathria M; Modena BD
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):44-56. PubMed ID: 31655122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
    Bakakos A; Loukides S; Usmani OS; Bakakos P
    Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choice of biologics in asthma endotypes.
    Wangberg H; Woessner K
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy.
    Nagase H; Suzukawa M; Oishi K; Matsunaga K
    Allergol Int; 2023 Jan; 72(1):11-23. PubMed ID: 36543689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variables predicting clinical remission among adults with severe asthma treated with biologic agents.
    Yeşilkaya S; Aksu K; Tuğçe Vural Solak G; Akkale O; Telli O; Tuğlu HC; Köycü Buhari G; Bahçecioğlu SN; Demir S
    Eur Ann Allergy Clin Immunol; 2024 Sep; 56(5):219-226. PubMed ID: 38054608
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma.
    Desai M; Haines A; Oppenheimer JJ
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):737-750. PubMed ID: 39389721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE; Resta E; Povero M; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Barbaro MPF
    Sci Rep; 2021 Mar; 11(1):5453. PubMed ID: 33750842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit.
    Pepper AN; Hanania NA; Humbert M; Casale TB
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1081-1088. PubMed ID: 33685606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
    Chan R; RuiWen Kuo C; Lipworth B
    J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety, durability of response, cessation and switching of biologics.
    Mohan A; Qiu AY; Lugogo N
    Curr Opin Pulm Med; 2024 May; 30(3):303-312. PubMed ID: 38426355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 38. Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.
    Demolder F; Vanderhelst E; Verbanck S; Schleich F; Louis R; Brusselle G; Sohy C; Michils A; Peché R; Pilette C; Hanon S
    Lung; 2024 Aug; 202(4):441-448. PubMed ID: 39007944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
    Casale TB; Chipps BE; Rosén K; Trzaskoma B; Haselkorn T; Omachi TA; Greenberg S; Hanania NA
    Allergy; 2018 Feb; 73(2):490-497. PubMed ID: 28859263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the current role of biologics in the management of patients with severe refractory asthma?
    Draikiwicz S; Oppenheimer J
    Ann Allergy Asthma Immunol; 2016 May; 116(5):383-7. PubMed ID: 27153737
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.